Reversal of the thrombin inhibitor dabigatran.

Back

ESC Premium Access

Reversal of the thrombin inhibitor dabigatran.

Session: Reversal of NOACs' effect: when and how?

Topic: Drug therapy

Speaker: Professor A. Niessner (Vienna, AT)

Event: ESC Congress 2016

Congress Presentation

About the speaker

Professor Alexander Niessner

Medical University of Vienna, Vienna (Austria)

9 presentations

1 follower

3 more presentations in this session

When should I use reversal agents for NOACs?

Speaker: Professor G. Lip (Liverpool, GB)

Access

ESC TV

Reversal of FXa inhibitors.

Speaker: Associate Professor S. Wassmann (Munich, DE)

Access

ESC TV

Will the availability of specific reversal agents change the use of NOACs?

Speaker: Professor F. Verheugt (Amsterdam, NL)

Access the full session

Reversal of NOACs' effect: when and how?

Speakers: Professor A. Niessner, Professor G. Lip, Associate Professor S. Wassmann, Professor F. Verheugt

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

Reversal of the thrombin inhibitor dabigatran.

About the speaker

Professor Alexander Niessner

3 more presentations in this session

When should I use reversal agents for NOACs?

Reversal of FXa inhibitors.

Will the availability of specific reversal agents change the use of NOACs?

Access the full session

Reversal of NOACs' effect: when and how?

About the event

ESC Congress 2016

ESC 365 is supported by